Filing identity and reporting period
The supplied filing is Skyline Medical Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2016. This does not match the request metadata naming Axe Compute Inc.; verify the issuer before relying on this summary.
Skyline describes itself as a development-stage medical-device company selling the STREAMWAY system for collecting and disposing of surgical fluids, plus related cleaning fluid and filters.
Financial results and liquidity
| Metric | Q1 2016 | Q1 2015 |
|---|---|---|
| Revenue | $96,905 | $151,274 |
| Gross margin dollars | $11,022 | $55,306 |
| Gross margin percentage | 11.4% | 36.6% |
| Net loss | $2,176,369 | $225,795 |
| Loss per share, basic and diluted | $0.12 | $0.07 |
| Operating cash flow | $(1,587,882) | $(5,231) |
| Investing cash flow | $(1,818,811) | $(7,700) |
- At March 31, cash was $1.54 million; certificates of deposit were $1.00 million and marketable securities were $802,850. Current assets totaled $3.82 million against current liabilities of $1.52 million.
- Total liabilities were $1.52 million, with no debt outstanding. Accounts payable and accrued expenses together were approximately $1.51 million.
- Total assets were $4.05 million and stockholders’ equity was $2.53 million. Accumulated deficit was $42.67 million.
- Cash fell by $3.32 million during the quarter. Financing provided $86,253, from option exercises.
Material changes versus the prior comparable period
- Revenue declined approximately 36%; management reported no STREAMWAY unit sales in Q1 2016 and attributed the decline partly to curtailed sales activity in late 2015 and focus on customer management.
- Gross margin percentage fell to about 11% from 37%. Management cited replacement of many units with a newer iteration at no charge, as well as early-stage production variability.
- Net loss increased substantially. General and administrative expense was $1.69 million, compared with a reported credit of $127,795 in Q1 2015; management attributed much of the increase to bonus differences, warrant-related compensation, exchange-offer legal and investor-relations costs, and sales-executive recruiting.
- Operating cash use rose to $1.59 million from $5,231. Interest expense fell to zero from $153,622 because no debt remained outstanding.
- Common shares outstanding rose from 5.21 million at December 31, 2015 to 53.26 million at March 31, largely reflecting cashless warrant exercises. The filing reports 66.16 million shares outstanding on May 19, 2016.
Outlook, risks, contingencies, and unusual items
- Management said it expected continued losses at least through the first three quarters of 2016. It anticipated gross margins could improve as production stabilizes and purchasing discounts increase, and expected revenue growth to outpace related cost growth; these are expectations, not assured results.
- Management reported negative operating cash flow of approximately $500,000 per month, predominantly due to legal and professional fees associated with tender offers, and expected it to decline to approximately $300,000 per month beginning in May 2016.
- The company said it would need additional financing for operations, sales expansion and product development. Financing might be unavailable or dilutive; failure to obtain funds could require limiting business activity. The filing reiterates substantial doubt about the company’s ability to continue as a going concern.
- Subsequent to quarter-end, a warrant exchange offer expired April 21, 2016: 1,770,556 Series A Warrants were exchanged for 18,059,671 Series B Warrants. Separately, 1,040,373 Series A Warrants were exercised cashlessly, issuing 10,454,136 common shares between March 31 and April 21.
- The filing says the company had sold 94 STREAMWAY units to date and reported approximately $20,000 of product sales revenue after quarter-end.
- Risks include dependence on future financing and product adoption, potential dilution, limited sales resources, medical-device competition and regulation, and possible limits on tax-loss utilization following an ownership change. The company also disclosed $914,391 deposited above insured limits at one bank.
- No legal proceedings were reported. Management concluded disclosure controls were effective as of March 31, 2016, and reported no material change in internal control over financial reporting. On May 11, the company announced that Josh Kornberg was no longer CEO, effective May 5, and that director Carl Schwartz became interim CEO.
Important facts for investors to verify
- Confirm issuer identity: the filing names Skyline Medical Inc., not Axe Compute Inc.
- Review the going-concern language, cash burn, expected monthly cash use, and the company’s financing plan and runway.
- Assess warrant and option terms, cashless-exercise dilution, the post-quarter warrant exchange, and updated shares outstanding.
- Verify unit sales, post-quarter revenue, hospital trial-to-purchase conversion, and whether management’s margin and sales expectations are being achieved.
- Reconcile reported expense comparisons and share-count changes against the underlying statements and subsequent filings.